The Activin A-blocking antibody sharply reduced new abnormal bone lesions in adults with fibrodysplasia ossificans progressiva.
Key Takeaways
- The FDA approved Pasatru (garetosmab-grts) for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder in which bone forms abnormally within soft tissues.
- In the Phase 3 OPTIMA trial, Pasatru reduced the number of new heterotopic ossification lesions by 90–94% versus placebo at Week 56.
- Pasatru is the second FDA-approved therapy for FOP, but uses a different mechanism from Ipsen’s Sohonos by directly neutralizing Activin A.
Data Snapshot
| Item | Details |
|---|---|
| Drug | Pasatru |
| Generic name | Garetosmab-grts |
| Developer | Regeneron |
| Modality | Fully human monoclonal antibody |
| Indication | Fibrodysplasia ossificans progressiva (FOP) in adults |
| Target | Activin A |
| Phase 3 trial | OPTIMA |
| Participants | 63 adults |
| New HO lesions | 90–94% reduction vs. placebo |
| Dosing | Intravenous infusion every 4 weeks |
| Existing FDA-approved competitor | Sohonos (palovarotene) |
FOP affects approximately 1 in 2 million people, with only about 800–900 diagnosed cases worldwide.
What Happened
The FDA approved Regeneron’s Pasatru (garetosmab-grts) for adults with FOP, a progressive genetic disorder in which muscles, tendons, ligaments and other connective tissues are gradually infiltrated by abnormal bone formation. (Reuters report)
Approval was supported by the Phase 3 OPTIMA trial, which enrolled 63 adults with FOP. At Week 56, garetosmab reduced the number of new heterotopic ossification lesions by 94% at 3 mg/kg and 90% at 10 mg/kg versus placebo. Regeneron also reported a greater than 99% reduction in the mean volume of new lesions in a post-hoc analysis. (Regeneron Phase 3 results)
Why It Matters
FOP is usually caused by gain-of-function mutations in ACVR1, also known as ALK2, a receptor involved in bone morphogenetic protein signaling. In FOP, Activin A abnormally activates mutant ACVR1 and drives signaling that promotes heterotopic ossification, or bone formation outside the normal skeleton.
Pasatru acts upstream by neutralizing Activin A, preventing it from triggering this abnormal signaling cascade. (Regeneron mechanism overview)
Curious about the molecular signaling behind FOP?
Read our BP Science explainer: [How Blocking Activin A Can Stop Abnormal Bone Formation in FOP]
Pasatru also offers a mechanistically distinct option from Sohonos (palovarotene), the first FDA-approved FOP therapy. Sohonos is an oral retinoic acid receptor gamma (RARγ) agonist that reduces downstream BMP/ALK2–SMAD1/5/8 signaling and suppresses abnormal bone formation. (FDA Sohonos review)
BP View
Pasatru is notable because it targets a molecular driver near the beginning of the FOP disease pathway rather than simply addressing the consequences of abnormal bone formation.
The 90–94% reduction in new HO lesions is particularly striking in a progressive disease where each new lesion can further restrict movement and daily function.
The approval also gives patients a second treatment option with a fundamentally different mechanism from Sohonos. For an ultra-rare disease with very limited therapeutic choices, having mechanistically distinct options is meaningful.
The next important step will be expanding the evidence into younger patients. Regeneron has indicated plans for pediatric development, which could be especially important in a genetic disease where abnormal bone formation often begins early in life.
Related Post
For another recent example of a novel therapeutic platform reaching late-stage clinical validation, read our previous analysis of Moderna’s personalized mRNA cancer therapy and its first positive Phase 3 result in melanoma.
About BP
Biopharma Perspective (BP) explains global biopharma news through strategic, clinical and market perspectives.
Leave a Reply